PerkinElmer
PerkinElmer Acquires Life Sciences Firm Covaris
Less than a year post-divestment from Revvity's life sciences and diagnostics business, PerkinElmer has inked a deal to expand its own life sciences portfolio.
Revvity Q2 Revenues Down on COVID Testing Declines; Organic Dx Revenues Rise
The firm reported 8 percent organic growth in diagnostics, excluding COVID-19, but it also saw lower spending on instruments, contracts, and technology deals.
The firm reported Thursday its Q1 revenues declined 30 percent as COVID-19 revenues dwindled but non-COVID organic revenues grew 6 percent.
In Brief This Week: PerkinElmer, Revvity, Personalis, DermTech, Mainz Biomed, More
News items for the week of May 1, 2023
In Brief This Week: Yourgene Health, Epigenomics, Bionano Genomics, Diatech Pharmacogenetics, More
News items for the week of April 24, 2023.